Cleave Therapeutics Appoints Amy Burroughs Chief Executive Officer and Completes $12 Million Equity Financing
Funds to Advance Second-Generation, Valosin-Containing Protein (VCP)/p97 Inhibitor, CB-5339, Through Early Clinical Development in AML and Solid Tumors SAN FRANCISCO–(BUSINESS…